{"title":"利用18F-FDG标准化摄取值和代谢肿瘤体积预测鼻咽癌局部衰竭。","authors":"Yuhao Lin, Jiawei Chen, Linghui Yan, Muling Deng, Jianming Ding","doi":"10.1159/000543950","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The aim was to evaluate the prognostic values of pretreatment 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) parameters for predicting local failure in nasopharyngeal carcinoma (NPC) patients in the intensity-modulated radiotherapy (IMRT) era.</p><p><strong>Methods: </strong>Retrospective analysis was performed on 759 patients with NPC who underwent pretreatment 18F-FDG PET. The optimal cutoff values for maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were determined by receiver operating characteristic curve analysis. Univariate and multivariate analysis was performed to identify the prognostic factors influencing local failure-free survival (LFFS). Survival curves for the different risk groups were plotted using the Kaplan-Meier survival analysis method and compared using the log-rank test.</p><p><strong>Results: </strong>The median follow-up period was 49.0 months (range: 3.0-118.0 months). The optimal cutoff of SUVmax and MTV were 7.44 and 22.21 mL, respectively. Patients with higher SUVmax and MTV were associated with worse LFFS. The survival curves of different groups were significantly separated. The univariate analysis showed the statistical significance of SUVmax, MTV, and their composite in LFFS (p = 0.002 for SUVmax; p = 0.001 for MTV; p < 0.002 for their composite). The multivariate analysis showed that higher SUVmax and MTV was an independent negative prognostic factor for LFFS (HR = 1.805, 95% CI: 1.004-3.245, p = 0.049). The subgroups of stages III-IV further confirmed the impact of SUVmax and MTV on LFFS (HR = 1.884, CI: 1.087-3.708, p = 0.026).</p><p><strong>Conclusion: </strong>Patients with higher SUVmax and MTV were associated with local failure as well as in the III-IV advanced stage.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Utilization of 18F-FDG Standardized Uptake Value and Metabolic Tumor Volume to Predict Local Failure in Nasopharyngeal Carcinoma.\",\"authors\":\"Yuhao Lin, Jiawei Chen, Linghui Yan, Muling Deng, Jianming Ding\",\"doi\":\"10.1159/000543950\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The aim was to evaluate the prognostic values of pretreatment 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) parameters for predicting local failure in nasopharyngeal carcinoma (NPC) patients in the intensity-modulated radiotherapy (IMRT) era.</p><p><strong>Methods: </strong>Retrospective analysis was performed on 759 patients with NPC who underwent pretreatment 18F-FDG PET. The optimal cutoff values for maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were determined by receiver operating characteristic curve analysis. Univariate and multivariate analysis was performed to identify the prognostic factors influencing local failure-free survival (LFFS). Survival curves for the different risk groups were plotted using the Kaplan-Meier survival analysis method and compared using the log-rank test.</p><p><strong>Results: </strong>The median follow-up period was 49.0 months (range: 3.0-118.0 months). The optimal cutoff of SUVmax and MTV were 7.44 and 22.21 mL, respectively. Patients with higher SUVmax and MTV were associated with worse LFFS. The survival curves of different groups were significantly separated. The univariate analysis showed the statistical significance of SUVmax, MTV, and their composite in LFFS (p = 0.002 for SUVmax; p = 0.001 for MTV; p < 0.002 for their composite). The multivariate analysis showed that higher SUVmax and MTV was an independent negative prognostic factor for LFFS (HR = 1.805, 95% CI: 1.004-3.245, p = 0.049). The subgroups of stages III-IV further confirmed the impact of SUVmax and MTV on LFFS (HR = 1.884, CI: 1.087-3.708, p = 0.026).</p><p><strong>Conclusion: </strong>Patients with higher SUVmax and MTV were associated with local failure as well as in the III-IV advanced stage.</p>\",\"PeriodicalId\":19497,\"journal\":{\"name\":\"Oncology\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000543950\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000543950","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Utilization of 18F-FDG Standardized Uptake Value and Metabolic Tumor Volume to Predict Local Failure in Nasopharyngeal Carcinoma.
Introduction: The aim was to evaluate the prognostic values of pretreatment 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) parameters for predicting local failure in nasopharyngeal carcinoma (NPC) patients in the intensity-modulated radiotherapy (IMRT) era.
Methods: Retrospective analysis was performed on 759 patients with NPC who underwent pretreatment 18F-FDG PET. The optimal cutoff values for maximum standardized uptake value (SUVmax) and metabolic tumor volume (MTV) were determined by receiver operating characteristic curve analysis. Univariate and multivariate analysis was performed to identify the prognostic factors influencing local failure-free survival (LFFS). Survival curves for the different risk groups were plotted using the Kaplan-Meier survival analysis method and compared using the log-rank test.
Results: The median follow-up period was 49.0 months (range: 3.0-118.0 months). The optimal cutoff of SUVmax and MTV were 7.44 and 22.21 mL, respectively. Patients with higher SUVmax and MTV were associated with worse LFFS. The survival curves of different groups were significantly separated. The univariate analysis showed the statistical significance of SUVmax, MTV, and their composite in LFFS (p = 0.002 for SUVmax; p = 0.001 for MTV; p < 0.002 for their composite). The multivariate analysis showed that higher SUVmax and MTV was an independent negative prognostic factor for LFFS (HR = 1.805, 95% CI: 1.004-3.245, p = 0.049). The subgroups of stages III-IV further confirmed the impact of SUVmax and MTV on LFFS (HR = 1.884, CI: 1.087-3.708, p = 0.026).
Conclusion: Patients with higher SUVmax and MTV were associated with local failure as well as in the III-IV advanced stage.
期刊介绍：
Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
